• Twist Bioscience priced an upsized underwritten follow-on offering of 3,125,000 common shares at USD 96 per share.
• Gross proceeds expected at USD 300 million; closing targeted for Aug. 6, 2026, subject to customary conditions.
• Underwriters hold a 30-day option to buy up to 468,750 additional shares at the offering price, less discounts and commissions.
• Proceeds earmarked for R&D, manufacturing expansion, product offerings, working capital, general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804240316) on August 05, 2026, and is solely responsible for the information contained therein.